Collectively, these results highlight the potential of Lycium barbarum glycopeptide as an innovative therapeutic agent for CD4 + T cell-associated autoimmune or inflammatory diseases, such as multiple sclerosis. The gene discussed is CD4; the disease is multiple sclerosis.